The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This...
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome – Primary endpoint achieved with both EPIDIOLEX doses compared...
This is a copy of the October 7th edition of our weekly Newsletter, which we have been publishing since October, 2015. Friends, With fewer than two weeks until the...
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million LONDON and CARLSBAD, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc...
GW Pharmaceuticals Announces Proposed Public Offering of ADSs LONDON and CARLSBAD, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”),...
Cannabis stocks, as measured by the Global Cannabis Stock Index, added to their August gains in September, rising 2.4% to 114.83: The index, which had 53 qualifying members that were...
This is a copy of the September 30th edition of our weekly Newsletter, which we have been publishing since October, 2015. Friends, As we enter the final quarter of...
The DEA has given Epidiolex, the CBD-based pharmaceutical derived from cannabis that was approved by the FDA for the treatment of rare forms of epilepsy in June, Schedule V...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This...
This is a copy of the August 12th edition of our weekly Newsletter, which we have been publishing since October, 2015. Friends, GW Pharma (NASDAQ: GWPH) made history earlier...
GW Pharmaceuticals (NASDAQ: GWPH) released financials for its fiscal 2018 Q3 after the close today and hosted a conference call for investors and analysts. Readers can access a full...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter....
This is a copy of the July 1st edition of our weekly Newsletter, which we have been publishing since October, 2015. Friends, With 2018 now halfway behind us, we...
FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy June 25, 2018 The U.S. Food and Drug Administration today...
Clearstream, the Luxembourg-based central securities depository that provides the clearing for the German stock market, has informed its customers that it will no longer be possible to settle securities...
Cannabis stocks, as measured by the Global Cannabis Stock Index, fell slightly again in May, declining 2.3% to 104.89, after advancing in the first part of the month and then pulling back:...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than $2.5 million per quarter...
Cannabis stocks, as measured by the Global Cannabis Stock Index, fell slightly in April, declining 0.5% to 107.33, after bouncing twice near 95 early in the month: The index, which went through...
Last week, GW Pharma (NASDAQ: GWPH) scored a milestone victory, as the thirteen-member panel at the Peripheral and Central Nervous System Drugs Advisory Committee, which met on April 19th to consider...
The potentially first botanically-derived FDA-approved cannabis-based product moved closer to approval today, as an Advisory Committee discussed the safety and efficacy of Epidolex, intended to treat seizures in children...
GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006 -Study did not meet its primary endpoint- -Company remains committed to continued development of GWP42006...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than $2.5 million per quarter....
After the close, GW Pharma (NASDAQ: GWPH) issued two press releases and hosted a conference call to review its FY18-Q1 ending 12/31/17. The company reported that the European Medicines...
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex(R) (cannabidiol) Study in The Lancet First well-controlled clinical study of cannabidiol in Lennox-Gastaut syndrome, a rare,...
